美国 · SEC FORM 4
COLLEGIUM PHARMACEUTICAL, INC
COLL · Nasdaq · CIK 0001267565 · Healthcare · Drug Manufacturers—Specialty & Generic
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
14 同一窗口内观察到的 Form 4 交易行
4 sales · 10 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
Showing the six most active owners; 1 additional owner(s) remain in Form 4 申报证据.
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot.—
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 5,516,880
- 上期报告
- 5,675,115
- 日均成交量
- 910,922
- 回补天数
- 6.1
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
本地 Form 4 历史中没有合资格的代码 P 股票买入。
Form 4 申报证据
46 transaction lines in the latest 365-day window; 417 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-08 | SANTINI GINO | 期权行权/转换 (M) | Common Stock | 8,700 | USD 16.49 | USD 143,463 | SEC 申报 ↗ |
| 2026-05-18 | Freund John Gordon | 卖出 (S) | Common Stock | 20 | USD 34.05 | USD 681 | SEC 申报 ↗ |
| 2026-05-15 | Freund John Gordon | 卖出 (S) | Common Stock | 4,127 | USD 34.54 | USD 142,547 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-06-08 | SANTINI GINO | 期权行权/转换 (M) | Common Stock | 8,700 | USD 16.49 | USD 143,463 | SEC 申报 ↗ |
| 2026-05-18 | Freund John Gordon | 卖出 (S) | Common Stock | 20 | USD 34.05 | USD 681 | SEC 申报 ↗ |
| 2026-05-15 | Freund John Gordon | 卖出 (S) | Common Stock | 4,127 | USD 34.54 | USD 142,547 | SEC 申报 ↗ |
| 2026-05-15 | Freund John Gordon | 期权行权/转换 (M) | Common Stock | 8,700 | USD 16.49 | USD 143,463 | SEC 申报 ↗ |
| 2026-05-14 | SANTINI GINO | 奖励/授予 (A) | Common Stock | 8,741 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-14 | Paya Carlos V | 奖励/授予 (A) | Common Stock | 8,741 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-14 | Lurker Nancy | 奖励/授予 (A) | Common Stock | 8,741 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-14 | Glancy Donovan Michael | 奖励/授予 (A) | Common Stock | 17,482 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-14 | Freund John Gordon | 奖励/授予 (A) | Common Stock | 8,741 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-14 | Balice-Gordon Rita J. | 奖励/授予 (A) | Common Stock | 8,741 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-14 | BOHLIN GAREN G | 奖励/授予 (A) | Common Stock | 8,741 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-13 | Lurker Nancy | 卖出 (S) | Common Stock | 4,500 | USD 35.97 | USD 161,865 | SEC 申报 ↗ |
| 2026-05-11 | BOHLIN GAREN G | 卖出 (S) | Common Stock | 8,700 | USD 37.18 | USD 323,466 | SEC 申报 ↗ |
| 2026-05-11 | BOHLIN GAREN G | 期权行权/转换 (M) | Common Stock | 8,700 | USD 16.49 | USD 143,463 | SEC 申报 ↗ |
| 2026-03-18 | Dieter David | 卖出 (S) | Common Stock | 13,976 | USD 34.92 | USD 488,042 | SEC 申报 ↗ |
| 2026-03-09 | Dieter David | 卖出 (S) | Common Stock | 6,224 | USD 36.65 | USD 228,110 | SEC 申报 ↗ |
| 2026-03-03 | Dreyer Scott | 卖出 (S) | Common Stock | 49,976 | USD 40.40 | USD 2,019,274 | SEC 申报 ↗ |
| 2026-02-10 | Tupper Colleen | 代扣税 (F) | Common Stock | 38,540 | USD 46.75 | USD 1,801,745 | SEC 申报 ↗ |
| 2026-02-10 | Tupper Colleen | 奖励/授予 (A) | Common Stock | 59,155 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-10 | Smith Thomas B | 代扣税 (F) | Common Stock | 17,435 | USD 46.75 | USD 815,086 | SEC 申报 ↗ |
| 2026-02-10 | Smith Thomas B | 奖励/授予 (A) | Common Stock | 37,042 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-10 | Karnani Vikram | 代扣税 (F) | Common Stock | 11,296 | USD 46.75 | USD 528,088 | SEC 申报 ↗ |
| 2026-02-10 | Karnani Vikram | 奖励/授予 (A) | Common Stock | 111,795 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-10 | Dreyer Scott | 代扣税 (F) | Common Stock | 31,592 | USD 46.75 | USD 1,476,926 | SEC 申报 ↗ |
| 2026-02-10 | Dreyer Scott | 奖励/授予 (A) | Common Stock | 49,725 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-10 | Dieter David | 代扣税 (F) | Common Stock | 2,781 | USD 46.75 | USD 130,012 | SEC 申报 ↗ |
| 2026-02-10 | Dieter David | 奖励/授予 (A) | Common Stock | 31,199 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-12-08 | Dreyer Scott | 卖出 (S) | Common Stock | 17,600 | USD 48.17 | USD 847,850 | SEC 申报 ↗ |
| 2025-12-08 | Dreyer Scott | 期权行权/转换 (M) | Common Stock | 17,600 | USD 15.90 | USD 279,840 | SEC 申报 ↗ |
| 2025-12-05 | Balice-Gordon Rita J. | 卖出 (S) | Common Stock | 3,650 | USD 47.03 | USD 171,660 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | COLL |
| CIK | 0001267565 |
| 行业 | Healthcare |
| 细分行业 | Drug Manufacturers—Specialty & Generic Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 417 transaction lines from 2020-01-02 to 2026-06-08 0 P purchase lines · 133 S sale lines · 284 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.